Whanin Pharm (016580) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Whanin Pharm KRW 11,707, price KRW 10,060, upside +16.4%, quality 42 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Whanin Pharm for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 9,230 KRW – 20,958 KRW · fair‑value band 7,898 KRW – 16,478 KRW · the 10,060 KRW price screens below the 11,707 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Whanin Pharm in your weekly email
Every Wednesday you see whether Whanin Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea.
Show more
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceutical products in South Korea. The company offers products, such as gastrointestinal, respiratory, cardiovascular, antidiabetic, antibiotic, antifungal, antihistamine, antiviral, antirheumatic, muscle relaxant, nonsteroidal anti-inflammatory, smoking cessation, erectile dysfunction, prostate disease, urinary disorder, osteoporosis, antiseizure, antidepressant, antipsychotic, central nervous system stimulant, anti-dementia, nootropic, alcohol use disorder, anti-Parkinson, multivitamin, external preparation, medical device, and sedative, hypnotic, and autonomic nervous system medications. The company was founded in 1978 and is headquartered in Seoul, South Korea.
Stock analysis
Whanin Pharm (016580) currently trades at 10,060 KRW, while our model-based Fair Value estimate is 11,707 KRW, implying the stock looks roughly 14.1% undervalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 15,261 KRW per share, and 17 of the 26 models we run sit above the 10,060 KRW price.
Bear case: the Dividend Discount group reads lowest at 2,600 KRW, and 9 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 7,898 KRW (bear) to 16,478 KRW (bull), the price of 10,060 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Whanin Pharm reported revenue of 255B KRW in FY2025 versus 178B KRW in FY2021, a compound +9.5%/yr. Reported net income was 13.6B KRW in FY2025, compounding −15.5%/yr from FY2021.
Key figures
Market cap 183B KRW (≈ $135M) · P/S ratio 0.69 · Dividend yield 3.0% · Net margin 5.3% · Return on equity 4.0% · Return on assets (EBIT) 6.4% · Operating margin 13.2% · Revenue (TTM) 266B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).
What moves the price
The share trades about 16% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 16%, 016580 screens cheaper than that median.
Fair Value models
Bear 7,898 KRWFair Value 11,707 KRWBull 16,478 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic)
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’11
’12
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−8.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.4%
Dividend (yield on the price)3.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 5%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +22.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside+16% · Above median
Profitability
Return on equity (TTM)4% · Below median
Return on assets2% · Below median
Net margin (TTM)6% · Below median
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth18% · Top 25%
Dividend yield (TTM)3.0% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Whanin Pharm Fair Value". https://www.fairvalue-calculator.com/stock/016580
Frequently asked questions
Is Whanin Pharm (016580) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 11,707 KRW versus a price of 10,060 KRW, about +16% upside (undervalued).
What is the fair value of 016580?
Our model-based fair value for Whanin Pharm is 11,707 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 10,060 KRW.
What is the quality score of 016580?
Whanin Pharm has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Whanin Pharm (016580)?
Our model-based price target is the fair value of 11,707 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 7,898 KRW, optimistic scenario 16,478 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Whanin Pharm stock forecast for 2026?
Our models put fair value at 11,707 KRW, about +16% upside versus a price of 10,060 KRW (undervalued). Cautious scenario 7,898 KRW, optimistic scenario 16,478 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Whanin Pharm (016580)?
Whanin Pharm reported trailing-twelve-month revenue of about 266B KRW (latest available figure, as of Sep 24, 2026).
Does Whanin Pharm pay a dividend?
Whanin Pharm currently shows a dividend yield of about 2.98% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Whanin Pharm (016580)?
For today's price to be fair in a discounted-cash-flow model, Whanin Pharm would have to grow free cash flow by +25.2 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 016580 use?
Our models discount Whanin Pharm at 11.6 %: a base by market capitalisation (micro), damped by beta 0.19, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Whanin Pharm that is +25.2 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Whanin Pharm (016580) delivered so far?
Over the past 5 years revenue at Whanin Pharm grew +8.3 % a year. The price currently implies +25.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Whanin Pharm (016580) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Whanin Pharm (+25.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Whanin Pharm (016580)?
The free-cash-flow yield on the price is 1.75 %: that much free cash flow Whanin Pharm produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Whanin Pharm (016580)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Whanin Pharm it is 11,707 KRW per share (as of Sep 24, 2026), against a price of 10,060 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Whanin Pharm stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 016580 trades below its calculated fair value: price 10,060 KRW, fair value 11,707 KRW, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 016580?
No. The price is what the market pays today (10,060 KRW); the fair value is what the company's own numbers justify (11,707 KRW). For Whanin Pharm the two are 1,647 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Whanin Pharm worth?
The market values Whanin Pharm at about 183B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 10,060 KRW; our models calculate a fair value of 11,707 KRW per share.
What do the bullish and bearish scenarios say about 016580?
Our models span a range for Whanin Pharm: cautious scenario 7,898 KRW, base 11,707 KRW, optimistic 16,478 KRW per share (as of Sep 24, 2026, price 10,060 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Whanin Pharm (016580)?
Balance-sheet figures for Whanin Pharm (as of Sep 24, 2026): return on equity 4.0%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 016580 from its 52-week high?
Whanin Pharm trades at 10,060 KRW, about 16% below its 52-week high of 11,930 KRW and 9% above the low of 9,230 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 11,707 KRW is for.
Which stocks are comparable to Whanin Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Whanin Pharm stock attractive at the current price?
The data as of Sep 24, 2026: price 10,060 KRW, calculated fair value 11,707 KRW (+16%), Quality Score 42/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 016580 calculated?
We run Whanin Pharm through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 11,707 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Whanin Pharm currently trades 16 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Whanin Pharm (016580)?
The closing price on Sep 23, 2026 was 10,060 KRW. Our model-based fair value is 11,707 KRW, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Whanin Pharm right now?
A fairly wide model range (7,898 KRW to 16,478 KRW) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Whanin Pharm
How large is the market capitalisation of Whanin Pharm (016580)?
The market capitalisation of Whanin Pharm is 183B KRW (≈ $135M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Whanin Pharm (016580)?
The price-to-sales ratio of Whanin Pharm is 0.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Whanin Pharm (016580)?
The dividend yield of Whanin Pharm is 3.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Whanin Pharm (016580)?
The net margin of Whanin Pharm is 5.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Whanin Pharm (016580)?
The return on equity (ROE) of Whanin Pharm is 4.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Whanin Pharm (016580)?
On an EBIT basis the return on assets of Whanin Pharm is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Whanin Pharm (016580)?
The operating margin of Whanin Pharm is 13.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Whanin Pharm (016580)?
Revenue at Whanin Pharm is growing +18.2% versus a year earlier (3y avg +8.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Whanin Pharm (016580)?
Earnings per share at Whanin Pharm are growing +20.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Whanin Pharm in the live analysis
One click puts Whanin Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
